In addition, among patients with T2DM, three were treated with Sodium-glucose Cotransporter-2 Inhibitors, 2 with Thiazolidinedione and 1 with Glucagon-like peptide-1 receptor agonists. Here, SLC5A2 is linked to type 2 diabetes mellitus.